151 related articles for article (PubMed ID: 12450567)
1. Inhibitory effect of reserpine on dopamine transporter function.
Metzger RR; Brown JM; Sandoval V; Rau KS; Elwan MA; Miller GW; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2002 Dec; 456(1-3):39-43. PubMed ID: 12450567
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel, inhibitory action of amiodarone on vesicular monoamine transport.
Haikerwal D; Dart AM; Little PJ; Kaye DM
J Pharmacol Exp Ther; 1999 Feb; 288(2):834-7. PubMed ID: 9918596
[TBL] [Abstract][Full Text] [Related]
3. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.
Hansen JP; Riddle EL; Sandoval V; Brown JM; Gibb JW; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2002 Mar; 300(3):1093-100. PubMed ID: 11861820
[TBL] [Abstract][Full Text] [Related]
4. Expression cloning of a reserpine-sensitive vesicular monoamine transporter.
Erickson JD; Eiden LE; Hoffman BJ
Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10993-7. PubMed ID: 1438304
[TBL] [Abstract][Full Text] [Related]
5. Functional expression of the plasma membrane serotonin transporter but not the vesicular monoamine transporter in human placental trophoblasts and choriocarcinoma cells.
Prasad PD; Hoffmans BJ; Moe AJ; Smith CH; Leibach FH; Ganapathy V
Placenta; 1996 May; 17(4):201-7. PubMed ID: 8761963
[TBL] [Abstract][Full Text] [Related]
6. Sex-dependent modulation of ethanol consumption in vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) knockout mice.
Hall FS; Sora I; Uhl GR
Neuropsychopharmacology; 2003 Apr; 28(4):620-8. PubMed ID: 12655306
[TBL] [Abstract][Full Text] [Related]
7. Ceramide-induced alterations in dopamine transporter function.
Riddle EL; Rau KS; Topham MK; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2003 Jan; 458(1-2):31-6. PubMed ID: 12498904
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.
Brown JM; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2001 Mar; 296(3):762-7. PubMed ID: 11181904
[TBL] [Abstract][Full Text] [Related]
9. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors.
Sandoval V; Riddle EL; Hanson GR; Fleckenstein AE
J Neurosci; 2002 Oct; 22(19):8705-10. PubMed ID: 12351745
[TBL] [Abstract][Full Text] [Related]
10. Reserpine affects differentially the density of the vesicular monoamine transporter and dihydrotetrabenazine binding sites.
Naudon L; Raisman-Vozari R; Edwards RH; Leroux-Nicollet I; Peter D; Liu Y; Costentin J
Eur J Neurosci; 1996 Apr; 8(4):842-6. PubMed ID: 9081637
[TBL] [Abstract][Full Text] [Related]
11. PCB-induced inhibition of the vesicular monoamine transporter predicts reductions in synaptosomal dopamine content.
Bemis JC; Seegal RF
Toxicol Sci; 2004 Aug; 80(2):288-95. PubMed ID: 15115888
[TBL] [Abstract][Full Text] [Related]
12. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters.
Miller DK; Crooks PA; Zheng G; Grinevich VP; Norrholm SD; Dwoskin LP
J Pharmacol Exp Ther; 2004 Sep; 310(3):1035-45. PubMed ID: 15121762
[TBL] [Abstract][Full Text] [Related]
13. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments.
Vander Borght T; Kilbourn M; Desmond T; Kuhl D; Frey K
Eur J Pharmacol; 1995 Dec; 294(2-3):577-83. PubMed ID: 8750721
[TBL] [Abstract][Full Text] [Related]
14. Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain.
Vilpoux C; Leroux-Nicollet I; Naudon L; Raisman-Vozari R; Costentin J
Neuropharmacology; 2000 Apr; 39(6):1075-82. PubMed ID: 10727718
[TBL] [Abstract][Full Text] [Related]
15. Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes.
Amenta F; Bronzetti E; Cantalamessa F; El-Assouad D; Felici L; Ricci A; Tayebati SK
J Neuroimmunol; 2001 Jul; 117(1-2):133-42. PubMed ID: 11431013
[TBL] [Abstract][Full Text] [Related]
16. Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system.
Wilhelm CJ; Johnson RA; Lysko PG; Eshleman AJ; Janowsky A
J Pharmacol Exp Ther; 2004 Sep; 310(3):1142-51. PubMed ID: 15102929
[TBL] [Abstract][Full Text] [Related]
17. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice.
Fumagalli F; Gainetdinov RR; Wang YM; Valenzano KJ; Miller GW; Caron MG
J Neurosci; 1999 Apr; 19(7):2424-31. PubMed ID: 10087057
[TBL] [Abstract][Full Text] [Related]
18. Vesicular monoamine transport inhibitors. Novel action at calcium channels to prevent catecholamine secretion.
Mahata M; Mahata SK; Parmer RJ; O'Connor DT
Hypertension; 1996 Sep; 28(3):414-20. PubMed ID: 8794826
[TBL] [Abstract][Full Text] [Related]
19. Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration.
Truong JG; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2004 May; 492(2-3):143-7. PubMed ID: 15178358
[TBL] [Abstract][Full Text] [Related]
20. A splice variant of the Drosophila vesicular monoamine transporter contains a conserved trafficking domain and functions in the storage of dopamine, serotonin, and octopamine.
Greer CL; Grygoruk A; Patton DE; Ley B; Romero-Calderon R; Chang HY; Houshyar R; Bainton RJ; Diantonio A; Krantz DE
J Neurobiol; 2005 Sep; 64(3):239-58. PubMed ID: 15849736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
